In contrast, while certain inconsistent studies on HIF2α exist, most studies demonstrated that HIF2α is a good oncogenic biomarker and target at least for ccRCC tumor therapeutics. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.